Mackenzie Financial’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-19,212
Closed -$505K – 1613
2026
Q1
$505K Buy
19,212
+15,381
+401% +$1.93M ﹤0.01% 1211
2025
Q4
$954K Sell
3,831
-32
-0.8% -$7.3K ﹤0.01% 1072
2025
Q3
$813K Sell
3,863
-3,050
-44% -$538K ﹤0.01% 1119
2025
Q2
$680K Buy
6,913
+2,507
+57% +$219K ﹤0.01% 1120
2025
Q1
$388K Buy
4,406
+658
+18% +$60.9K ﹤0.01% 1288
2024
Q4
$271K Buy
3,748
+3,122
+499% +$214K ﹤0.01% 1428
2024
Q3
$49.4K Buy
+626
New +$48.2K ﹤0.01% 1537

Other funds holding GOSS

Mackenzie Financial's GOSS Position: Q2 2026 in Review

Mackenzie Financial sold out of Gossamer Bio (GOSS) in Q2 2026, closing a stake of 19,212 shares — an estimated $505K sold.

Mackenzie Financial first reported a position in GOSS in Q3 2024 and held it in 7 quarters. The position peaked at $954K in Q4 2025. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Mackenzie Financial reported no remaining Gossamer Bio position as of Q2 2026 after selling out during the quarter.
  • Mackenzie Financial sold 19,212 Gossamer Bio shares in Q2 2026, an estimated $505K.
  • Mackenzie Financial first reported a position in Gossamer Bio in Q3 2024 and held it in 7 quarters.
  • Mackenzie Financial's Gossamer Bio position peaked at $954K in Q4 2025.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.